Application of Extracellular Gadolinium-based MRI Contrast Agents and the Risk of Nephrogenic Systemic Fibrosis

 

 Permissions and Reprints

Abstract

Nephrogenic systemic fibrosis (NSF) is a serious, sometimes fatal disease. Findings in recent years have shown that a causal association between gadolinium containing contrast media and NSF is most likely. Therefore, the regulatory authorities have issued guidelines on the use of gadolinium-containing contrast media which have reduced the number of new cases of NSF to almost zero. However, it is for precisely this reason that the greatest care must still be taken to ensure that these guidelines are complied with. The most important factors are renal function, the quantity of gadolinium administered and coexisting diseases such as inflammation. All of these factors crucially influence the quantity of gadolinium released from the chelat in the body. This free gadolinium is thought to be the trigger for NSF. Other important factors are the stability of the gadolinium complex and furthermore the route of its elimination from the body. Partial elimination via the liver might be an additional protective mechanism. In conclusion, despite the NSF risk, contrast-enhanced MRI is a safe diagnostic procedure which can be used reliably and safely even in patients with severe renal failure, and does not necessarily have to be replaced by other methods.

Key Points:

• Despite the inherent risk of NSF, a MR investigation must not be denied to a patient provided there are sufficient indications and the possible benefits outweigh the risk.

• The risk of NSF can be minimized by adhering to the federal guidelines and using the minimal necessary Gd dose.

• It is recommended to measure the eGFR in all patients prior to the administration of a Gd-chelate. However, it is mandatory only when using agents of the high risk group.

• Gd-chelates should classified into two risk classes. No differences should be made between low and medium risk agents.

• Partial elimination of the agent by the liver may have a protective effect against NSF.

Citation Format:

• Heverhagen JT, Krombach GA, Gizewski E. Application of Extrcellular Gadolinium-based MRI Contrast Agents and the Risk of Nephrogenic Systemic Fibrosis. Fortschr Röntgenstr 2014; 186: 661 – 669

Zusammenfassung

Die Nephrogene Systemische Fibrose (NSF) ist eine schwerwiegende Erkrankung, welche auch zum Tode führen kann. Ein kausaler Zusammenhang zwischen gadoliniumhaltigen Kontrastmitteln und NSF ist aufgrund der Erkenntnisse der letzten Jahre als gegeben anzunehmen. Aus diesem Grund haben die Zulassungsbehörden die Kontraindikationen für die Anwendung gadoliniumhaltiger Kontrastmittel erweitert. Die Umsetzung dieser Anwendungseinschränkungen hat die Anzahl der neu aufgetretenen NSF-Fälle auf nahezu Null reduziert. Trotzdem sollte weiterhin streng auf die Einhaltung der Indikationen und Kontraindikationen geachtet werden, ohne dabei Patienten dringend indizierte Untersuchungen mit gadoliniumhaltigen Kontrastmitteln zu verwehren. Die wichtigsten Faktoren für die Entstehung einer NSF sind die eingeschränkte Nierenfunktion, die Menge des applizierten Gadoliniums sowie zusätzliche Erkrankungen wie beispielsweise Entzündungen und die hiermit einhergehende Absenkung des pH-Wertes. Diese Faktoren haben einen entscheidenden Einfluss auf die im Organismus aus dem Kontrastmittelchelat frei werdenden Gadoliniumionen, den mutmaßlichen Auslöser der NSF. Hinzu kommt die Stabilität des Gadoliniumkomplexes und weiterhin auch der Ausscheidungsweg aus dem Organismus. Vermutlich stellt eine partielle Ausscheidung über die Leber einen zusätzlichen protektiven Mechanismus dar. Zusammenfassend kann festgehalten werden, dass die kontrastverstärkte MRT trotz des NSF-Risikos ein sicheres diagnostisches Verfahren darstellt, welches bei Beachtung der Anwendungsrichtlinien und aktuellen Empfehlungen auch bei Patienten mit schwerer Niereninsuffizienz sicher eingesetzt werden kann und nicht zwingend durch andere Verfahren ersetzt werden muss.

• Literatur

• 1 Cowper SE, Robin HS, Steinberg SM et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. The Lancet 2000; 356: 1000-1001
  CrossrefPubMedGoogle Scholar
• 2 Perez-Rodriguez J, Lai S, Ehst BD et al. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment – report of 33 cases. Radiology 2009; 250: 371-377
  CrossrefPubMedGoogle Scholar
• 3 Kribben A, Witzke O, Hillen U et al. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J Am Coll Cardiol 2009; 53: 1621-1628
  CrossrefPubMedGoogle Scholar
• 4 Jalandhara N, Arora R, Batuman V. Nephrogenic Systemic Fibrosis and Gadolinium-Containing Radiological Contrast Agents: An Update. Clin Pharmacol Ther 2011; 89: 920-923
  CrossrefPubMedGoogle Scholar
• 5 Grobner T. Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 2006; 21: 1104-1108
  PubMedGoogle Scholar
• 6 Marckmann P, Skov L, Rossen K et al. Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging. J Am Soc Nephrol 2006; 17: 2359-2362
  CrossrefPubMedGoogle Scholar
• 7 Bennett CL, Qureshi ZP, Sartor AO et al. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clinical Kidney Journal 2012; 5: 82-88
  CrossrefPubMedGoogle Scholar
• 8 Gupta A, Shamseddin MK, Khaira A. Pathomechanisms of nephrogenic systemic fibrosis: new insights. Clin Exp Dermatol 2011; 36: 763-768
  CrossrefPubMedGoogle Scholar
• 9 Collidge TA, Thomson PC, Mark PB et al. Gadolinium-enhanced MR Imaging and Nephrogenic Systemic Fibrosis: Retrospective Study of a Renal Replacement Therapy Cohort. Radiology 2007; 245: 168-175
  CrossrefPubMedGoogle Scholar
• 10 Wahba IM, Simpson EL, White K. Gadolinium Is Not the Only Trigger for Nephrogenic Systemic Fibrosis: Insights From Two Cases and Review of the Recent Literature. Am J Transplant 2007; 7: 2425-2432
  CrossrefPubMedGoogle Scholar
• 11 Cowper SE, Boyer PJ. Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep 2006; 8: 151-157
  CrossrefPubMedGoogle Scholar
• 12 Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. European Journal of Radiology 2008; 66: 191-199
  CrossrefPubMedGoogle Scholar
• 13 Becker S, Walter S, Witzke O et al. The German registry for nephrogenic systemic fibrosis: findings from 23 patients. Clin Nephrol 2010; 73: 426-430
  CrossrefPubMedGoogle Scholar
• 14 FDA Public Health Advisory. Gadolinium-containing Contrast Agents for Magnetic Resonance Imaging (MRI). 2006 www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053112.htm (Stand 20.08.2013)
  PubMedGoogle Scholar
• 15 FDA. New warnings required on use of gadolinium-based contrast agents. 2007 www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm225286.htm (Stand 20.08.2013)
  PubMedGoogle Scholar
• 16 GE Healthcare. Wichtige Information zur Arzneimittelsicherheit Omniscan und nephrogener systemischer Fibrose. 2/2007 www.bfarm.de/SharedDocs/1_Downloads/DE/Pharmakovigilanz/roteHandBriefe/2007/rhb-omniscan.pdf?__blob=publicationFile (Stand 20.08.2013)
  PubMedGoogle Scholar
• 17 Bayer Health Care. Aktualisierte Sicherheitsinformation zu Magnevist und nephrogener systemischer Fibrose (NSF). 6/2007 www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2007/46-20070625.pdf (Stand 20.08.2013)
  PubMedGoogle Scholar
• 18 High WA, Ayers RA, Chandler J et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56: 21-26
  CrossrefPubMedGoogle Scholar
• 19 Salomonsson M, Braunstein TH, Holstein-Rathlou NH et al. Na+-independent, nifedipine-resistant rat afferent arteriolar Ca2+ responses to noradrenaline: possible role of TRPC channels. Acta Physiol (Oxf) 2010; 200: 265-278
  CrossrefPubMedGoogle Scholar
• 20 Caille JM, Lemanceau B, Bonnemain B. Gadolinium as a contrast agent for NMR. Am J Neuroradiol 1983; 4: 1041-1042
  PubMedGoogle Scholar
• 21 Penfield JG, Reilly Jr RF. What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol 2007; 3: 654-668
  PubMedGoogle Scholar
• 22 Frenzel T, Lengsfeld P, Schirmer H et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 2008; 43: 817-828
  CrossrefPubMedGoogle Scholar
• 23 Schmitt-Willich H. Stability of linear and macrocyclic gadolinium based contrast agents. Br J Radiol 2007; 80: 581-582
  CrossrefPubMedGoogle Scholar
• 24 Pietsch H, Pering C, Lengsfeld P et al. Evaluating the role of zinc in the occurrence of fibrosis of the skin: A preclinical study. J Magn Reson Imaging 2009; 30: 374-383
  CrossrefPubMedGoogle Scholar
• 25 Marckmann P, Skov L, Rossen K et al. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007; 22: 3174-3178
  CrossrefPubMedGoogle Scholar
• 26 Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008; 43: 141-144
  CrossrefPubMedGoogle Scholar
• 27 Prince MR, Zhang H, Morris M et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008; 248: 807-816
  CrossrefPubMedGoogle Scholar
• 28 Sato T, Ito K, Tamada T et al. Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: Evaluation with inductively coupled plasma mass spectrometry (ICP-MS). Magn Reson Imaging 2013; Epub ahead of print
  PubMedGoogle Scholar
• 29 Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol 1998; 33: 798-809
  PubMedGoogle Scholar
• 30 Sieber MA, Lengsfeld P, Walter J et al. Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson Imaging 2008; 27: 955-962
  CrossrefPubMedGoogle Scholar
• 31 Sieber MA, Steger-Hartmann T, Lengsfeld P et al. Gadolinium-based contrast agents and NSF: Evidence from animal experience. J Magn Reson Imaging 2009; 30: 1268-1276
  CrossrefPubMedGoogle Scholar
• 32 Sieber MA, Pietsch H, Walter J et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 2008; 43: 65-75
  CrossrefPubMedGoogle Scholar
• 33 Sieber MA, Lengsfeld P, Frenzel T et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 2008; 18: 2164-2173
  CrossrefPubMedGoogle Scholar
• 34 Lorusso V, Arbughi T, Tirone P et al. Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance). J Comput Assist Tomogr 1999; 23 (Suppl. 01) S181-S194
  CrossrefPubMedGoogle Scholar
• 35 Schuhmann-Giampieri G. Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging 167. Invest Radiol 1993; 28: 753-761
  CrossrefPubMedGoogle Scholar
• 36 Han G, Nguyen LN, Macherla C et al. Nitric Oxide-Releasing Nanoparticles Accelerate Wound Healing by Promoting Fibroblast Migration and Collagen Deposition. Am J Pathol 2012; 180: 1465-1473
  CrossrefPubMedGoogle Scholar
• 37 Haemel AK, Sadowski EA, Shafer MM et al. Update on nephrogenic systemic fibrosis: are we making progress?. Int J Dermatol 2011; 50: 659-666
  CrossrefPubMedGoogle Scholar
• 38 Yang L, Krefting I, Gorovets A et al. Nephrogenic Systemic Fibrosis and Class Labeling of Gadolinium-based Contrast Agents by the Food and Drug Administration. Radiology 2012; 265: 248-253
  CrossrefPubMedGoogle Scholar
• 39 Giersig C (BfArM). Sicherheit von gadoliniumhaltigen Kontrastmitteln unter dem Aspekt der Nephrogenen Systemischen Fibrose, Vortrag im Rahmen des Symposiums „Kontrast verstärkte MR-Untersuchungen – praxisnah für den Alltag“ in Stuttgart 10/2010.
  PubMedGoogle Scholar
• 40 EMEA. Assessment report for gadolinium-containing contrast agents. 2010 www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/gadolinium_31 / WC500099538.pdf (Stand 20.08.2013)
  PubMedGoogle Scholar
• 41 Schneider G, Maas R, Schultze KL et al. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol 2003; 38: 85-94
  CrossrefPubMedGoogle Scholar
• 42 Achenbach M, Figiel JH, Burbelko M et al. Prospective comparison of image quality and diagnostic accuracy of 0.5 molar gadobenate dimeglumine and 1.0 molar gadobutrol in contrast-enhanced run-off magnetic resonance angiography of the lower extremities. J Magn Reson Imaging 2010; 32: 1166-1171
  CrossrefPubMedGoogle Scholar
• 43 Bauner KU, Reiser MF, Huber AM. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine. Invest Radiol 2009; 44: 95-104
  CrossrefPubMedGoogle Scholar
• 44 Thomsen HS, Morcos SK, Almen T et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 2013; 23: 307-318
  CrossrefPubMedGoogle Scholar
• 45 American College of Radiology. Manual on Cotrast Media, Version 9. 2013 www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2013_Contrast_Media.pdf (Stand 20.08.2013)
  PubMedGoogle Scholar
• 46 ESUR. Guidelines Version 8.1. 2013 http://www.esur.org/guidelines/en/index.php (Stand 20.08.2013)
  PubMedGoogle Scholar
• 47 ESUR. Summary NSF. 2013 http://www.esur.org/esur-guidelines/nsf (Stand 20.08.2013)
  PubMedGoogle Scholar
• 48 Yoshikawa K, Davies A. Safety of ProHance in special populations. Eur Radiol 1997; 7 (Suppl. 05) 246-250
  CrossrefPubMedGoogle Scholar
• 49 Kalb RE, Helm TN, Sperry H et al. Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury. Br J Dermatol 2008; 158: 607-610
  PubMedGoogle Scholar
• 50 Perez-Rodriguez J, Lai S, Ehst BD et al. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment – report of 33 cases. Radiology 2009; 250: 371-377
  CrossrefPubMedGoogle Scholar
• 51 Bindschedler M Swissmedic; Sicherheitsrelevante Information zu gadoliniumhaltigen Kontrastmitteln. Schweizerische Ärztezeitung 2006; 87: 29/30 1323 www.saez.ch/docs/saez/archiv/de/2006/2006-30/2006-30-686.PDF (Stand 20.08.2013)
  PubMedGoogle Scholar
• 52 Elmholdt TR, Pedersen M, Jorgensen B et al. Nephrogenic systemic fibrosis is only found among gadolinium-exposed kidney-insufficient patients: a case-control study from Denmark. Br J Dermatol 2011; 165: 828-836
  CrossrefPubMedGoogle Scholar
• 53 Guerbet. Updated safety information. 2011 www.guerbet.co.kr/fileadmin/user_upload/websites/site_co/2011_28_February-Updated_information_about_NSF.pdf (Stand 20.08.2013)
  PubMedGoogle Scholar
• 54 Bayer. Reports of NSF/NSF-like symptoms in possible association with the administration of Gadolinium-based contrast agents of Bayer. www.diagnostic-imaging.bayerscheringpharma.de/html/pdf/hcp/nsf/NSF_website_NSF_ reports_Jan11.pdf (Stand 19.09.2011)
  PubMedGoogle Scholar
• 55 Neumann H. Optimark (gadoversetamide) U. S. Food and Drug Administration, Joint Meeting of the Cardiovascular and Renal Drugs and Drug Safety and Risk Management. 2009 www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM196229.pdf (Stand 20.08.2013)
  PubMedGoogle Scholar
• 56 Bracco. Info-Brief NSF. Auf Anfrage bei Services.professional@bracco.com, (Stand 20.08.2013)
  PubMedGoogle Scholar
• 57 Bayer Health Care. Briefing Document for Gadobutrol Injection. 2011 www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM240357.pdf (Stand 20.08.2013)
  PubMedGoogle Scholar

• Supplementary Material